Английская Википедия:BriLife
Шаблон:Short description Шаблон:Use dmy dates Шаблон:Expand Hebrew Шаблон:Infobox drug Шаблон:COVID-19 pandemic sidebar BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]
References
External links
- IIBR-100 entry at Stanford Medicine
- Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
Шаблон:ScholiaШаблон:Commons categoryШаблон:Vaccines Шаблон:COVID-19 pandemic Шаблон:Portal bar
Шаблон:Vaccine-stub Шаблон:COVID19-vaccine-stub
- Английская Википедия
- Clinical trials related to COVID-19
- Israeli COVID-19 vaccines
- Science and technology in Israel
- Viral vector vaccines
- Drugs not assigned an ATC code
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии